** Brokerage Raymond James resumes coverage on drugmaker BridgeBio Pharma BBIO.O with "outperform" rating; sets PT at $57, a 66.4% upside to the stock's last close

** Brokerage anticipates BBIO's launch of heart disease drug Attruby to be faster than expected, even with a significant discount on revenues after 2028 due to potential pricing pressure from the loss of exclusivity for Pfizer's PFE.N tafamidis

** "We expect it to gain meaningful market share in the newly diagnosed population," brokerage adds

** BBIO can leverage its drugs Encaleret and BBP-418 to form partnerships and improve finances — brokerage

** 14 out of 16 brokerages rate the stock "buy" or higher, 2 rate it "hold", per data compiled by LSEG

** Stock has fallen 4.1% in the past 12 months

(Reporting by Padmanabhan Ananthan)

((Padmanabhan.Ananthan@thomsonreuters.com))